Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2026-015671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Zehra Ef Demir und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: CD40 Antigens, Breast Neoplasms, High-Intensity Focused Ultrasound Ablation. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, UVA Cancer Biology Training Grant.
Abstract (Originalsprache)
Background
Focused ultrasound thermal ablation (T-FUS) is a clinically accessible, non-invasive modality capable of inducing rapid tumor cytoreduction while mobilizing early immunologic danger signals. However, its capacity to synergize with potent co-stimulatory immunotherapies in breast cancer (BC) remains undefined. Here, we investigated whether subtotal T-FUS cooperates with CD40 agonism to elicit durable, T cell-dependent tumor control across immunologically and molecularly distinct murine BC models.
Methods
Subtotal ultrasound-guided T-FUS was applied to E0771, BRPKP110, EMT6, and 4T1 tumors in mice treated with systemic agonistic αCD40. Histology, ATP bioluminescence imaging, and multispectral flow cytometry were used to define acute tumor injury and immune remodeling. Therapeutic efficacy was evaluated by tumor growth, survival, T-cell depletion, and contralateral tumor rechallenge.
Results
Partial thermal ablation triggered canonical immunogenic cell-death signatures and acute remodeling of intratumoral myeloid populations, while expanding circulating CD4+ and CD8+ T cells. When layered onto this immunogenic milieu, αCD40 markedly constrained tumor outgrowth, yielding significant reductions in tumor burden across all models and complete tumor eradication in 30% of E0771 tumors, with additional complete responses in BRPKP110 and EMT6. Combination treatment also extended survival across three of four models. Efficacy required both CD4+ and CD8+ T cells, as depletion of either compartment abrogated tumor control. Complete responders mounted robust systemic immunity, rejecting contralateral tumor rechallenge with 100% protection and displaying persistent effector-memory T-cell activation.
Conclusions
Subtotal T-FUS cooperates with CD40 agonism to drive durable, T cell-dependent BC regression and immunologic memory. These findings establish T-FUS as an immune-potentiating partner for CD40 agonism and position this combination as a clinically scalable, in situ vaccination-like strategy with potential to broaden immunotherapy benefit across breast cancer subtypes, including luminal tumors that remain largely refractory to immune checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
- Department of Pathology, University of Virginia, Charlottesville, Virginia, USA.
- Focused Ultrasound Immuno-Oncology Center, University of Virginia, Charlottesville, Virginia, USA.
- Department of Biomedical Engineering, The George Washington University, Washington, DC, USA.
- Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA nds3sa@virginia.edu.
Förderung
- NIH HHS
- NCI NIH HHS
- UVA Cancer Biology Training Grant
- UVA SEAS Endowed Graduate Fellowships
- UVA Comprehensive Cancer Center Training Fellowship
- UVA Jefferson Scholars Foundation Fellowship
- Focused Ultrasound Foundation
- UVA Focused Ultrasound Immuno-Oncology (FUSION) Center
Zitieren
APA
Demir, Z. E., Kim, A., Ak, B. G., Lee, M. S., Sherlock, T., Maslova, S. O., Thede, A. T., Talebibarmi, P., DeWitt, M. R., Rutkowski, M., & Sheybani, N. D. (2026). Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-015671
Vancouver
Demir ZE, Kim A, Ak BG, Lee MS, Sherlock T, Maslova SO, et al. Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-015671
BibTeX
@article{Demir2026,
author = {Demir, Zehra Ef and Kim, Aeryon and Ak, Beyzanur G and Lee, Micaiah S and Sherlock, Thomas and Maslova, Stefanyda O and Thede, Andrew T and Talebibarmi, Pouria and DeWitt, Matthew R and Rutkowski, Melanie and Sheybani, Natasha D},
title = {Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2026-015671}
}
EUVIMED